The Clinical Pharmacology of Intranasal l-Methamphetamine
We studied the pharmacology of l-methamphetamine, the less abused isomer, when used as a nasal decongestant.
Methods: 12 subjects self-administered l-methamphetamine from a nonprescription inhaler at the recommended dose (16 inhalations over 6 hours) then at 2 and 4 (32 and 64 inhalations) times this dose.
In a separate session intravenous phenylephrine (200 ug) and l-methamphetamine (5 mg) were given to define alpha agonist pharmacology and bioavailability. Physiological, cardiovascular, pharmacokinetic, and subjective effects were measured.
Results: Plasma l-methamphetamine levels were often below the level of quantification so bioavailability was estimated by comparing urinary excretion of the intravenous and inhaled doses, yielding delivered dose estimates of 74.0+/-56.1, 124.7+/-106.6, and 268.1+/-220.5 ug for ascending exposures (mean 4.2+/-3.3 ug/inhalation).
Physiological changes were minimal and not dose-dependent. Small decreases in stroke volume and cardiac output suggesting mild cardiodepression were seen.
Conclusions: Inhaled l-methamphetamine delivered from a non-prescription product produced minimal effects but may be a cardiodepressant.
Author: John Mendelson, Dana McGlothlin, Debra S Harris, Elyse Foster, Tom Everhart, Peyton Jacob and Reese Jones
Credits/Source: BMC Clinical Pharmacology 2008, 8:4
Published on: 2008-07-21
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
